Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Pazopanib Monotherapy in Relapsed or Refractory Germ Cell Tumors
2012-004910-33Phase 2Completed
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- Dec 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pazopanib in germ cell tumor (GCT), Germ Cell Testicular Cancer and extragonadal germ cell tumor (EGGCT), sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Primary endpoint: 3-month progression-free survival. Started Dec 2012; status: completed.
02
Drugs
pazopanib
03
Conditions
germ cell tumor (GCT)Germ Cell Testicular Cancerextragonadal germ cell tumor (EGGCT)
Beyond the preview
Go deeper on 2012-004910-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004910-33.